Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

TherapeuticsMD, Inc. - Common Stock (NQ: TXMD )

1.080 -0.030 (-2.70%)
Streaming Delayed Price Updated: 11:54 AM EST, Jan 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about TherapeuticsMD, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
TherapeuticsMD Announces Third Quarter 2024 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD And 2 Other Stocks Under $2 Executives Are Buying
Via Benzinga
TXMD Stock Earnings: TherapeuticsMD Reported Results for Q2 2024
TherapeuticsMD just reported results for the second quarter of 2024. 
Via InvestorPlace
TherapeuticsMD Announces Second Quarter 2024 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
TXMD Stock Earnings: TherapeuticsMD Reported Results for Q4 2023
TherapeuticsMD just reported results for the fourth quarter of 2023. 
Via InvestorPlace
TXMD Stock Earnings: TherapeuticsMD Reported Results for Q1 2024
TherapeuticsMD just reported results for the first quarter of 2024. 
Via InvestorPlace
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
TherapeuticsMD Announces First Quarter 2024 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Announces Full Year 2023 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
5 Value Stocks In The Healthcare Sector
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
TherapeuticsMD Announces Third Quarter 2023 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
Nasdaq Jumps 100 Points; US Trade Deficit Widens In September
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Tuesday The Dow traded up 0.19% to 34,159.14 while the NASDAQ rose 0.84% to 13,631.99. The... 
Via Benzinga
Topics Stocks
Exposures US Equities
TherapeuticsMD Announces Second Quarter 2023 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Announces First Quarter 2023 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
  During the session on Thursday, 461 stocks hit new 52-week lows. 
Via Benzinga
TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition
From TherapeuticsMD, Inc.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with a breakdown of the biggest pre-market stock movers traders will want to watch for Monday! 
Via InvestorPlace
TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma
From TherapeuticsMD, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Announces Third Quarter 2022 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Announces Additional $7 Million Private Placement
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Announces $7 Million Private Placement
From TherapeuticsMD, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Benitec Biopharma (NASDAQ:BNTC) shares increased by 9.8% to $0.35 during Tuesday's after-market session. The company's market cap stands at $9.0 million. 
Via Benzinga
TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers
From TherapeuticsMD, Inc.
Via Business Wire
Looking Into TherapeuticsMD's Return On Capital Employed
According to Benzinga Pro, during Q2, TherapeuticsMD (NASDAQ:TXMD) earned $112.28 million, a 329.05% increase from the preceding quarter. TherapeuticsMD also posted a total of $28.56 million in sales,... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.